Shares of MEDNAX Inc (NYSE:MD) have received an average recommendation of “Hold” from the eight analysts that are covering the company. Eight investment analysts have rated the stock with a hold recommendation. The average 1-year price target among brokers that have covered the stock in the last year is $68.60.
A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a report on Thursday, April 13th. Jefferies Group LLC reissued a “hold” rating and set a $63.00 price objective on shares of MEDNAX in a report on Wednesday, February 8th. They noted that the move was a valuation call. JPMorgan Chase & Co. reissued a “neutral” rating and set a $69.00 price objective on shares of MEDNAX in a report on Friday, March 10th. Finally, Robert W. Baird downgraded shares of MEDNAX from an “outperform” rating to a “neutral” rating and set a $72.00 target price for the company. in a research report on Tuesday, March 21st.
COPYRIGHT VIOLATION WARNING: “MEDNAX Inc (MD) Receives $67.67 Consensus Target Price from Brokerages” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/04/21/brokerages-set-mednax-inc-md-target-price-at-67-67-updated.html.
MEDNAX (NYSE:MD) traded down 1.04% on Tuesday, hitting $60.66. The stock had a trading volume of 655,897 shares. MEDNAX has a 1-year low of $59.36 and a 1-year high of $76.96. The company has a market cap of $5.63 billion, a P/E ratio of 17.38 and a beta of 0.67. The stock has a 50 day moving average price of $68.98 and a 200 day moving average price of $67.26.
MEDNAX (NYSE:MD) last announced its quarterly earnings data on Tuesday, February 7th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by $0.06. The company had revenue of $831 million for the quarter, compared to analysts’ expectations of $842.15 million. MEDNAX had a net margin of 10.21% and a return on equity of 13.59%. MEDNAX’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period last year, the firm earned $1.13 earnings per share. On average, equities research analysts expect that MEDNAX will post $4.25 EPS for the current fiscal year.
In other MEDNAX news, Director Enrique Sosa sold 10,668 shares of the company’s stock in a transaction dated Thursday, February 23rd. The shares were sold at an average price of $69.65, for a total value of $743,026.20. Following the completion of the transaction, the director now owns 21,923 shares in the company, valued at $1,526,936.95. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Vivian Lopez-Blanco sold 15,164 shares of the company’s stock in a transaction dated Friday, February 17th. The stock was sold at an average price of $70.01, for a total transaction of $1,061,631.64. Following the completion of the transaction, the chief financial officer now owns 59,097 shares of the company’s stock, valued at approximately $4,137,380.97. The disclosure for this sale can be found here. Insiders have sold 86,296 shares of company stock valued at $5,959,391 over the last 90 days. 2.40% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of MEDNAX by 5.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,604 shares of the company’s stock worth $106,000 after buying an additional 77 shares during the period. Ledyard National Bank raised its stake in shares of MEDNAX by 19.0% in the first quarter. Ledyard National Bank now owns 1,725 shares of the company’s stock worth $120,000 after buying an additional 275 shares during the period. First Bank & Trust acquired a new stake in shares of MEDNAX during the fourth quarter worth approximately $175,000. 1st Global Advisors Inc. acquired a new stake in shares of MEDNAX during the third quarter worth approximately $205,000. Finally, Cigna Investments Inc. New acquired a new stake in shares of MEDNAX during the fourth quarter worth approximately $224,000. Institutional investors and hedge funds own 99.16% of the company’s stock.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX Inc and related companies with MarketBeat.com's FREE daily email newsletter.